Coverage / AUTL / Trade Card

AUTL

Autolus Therapeutics PLC

OPPORTUNISTIC BUY Analysis generated 2026-11-14 Market data as of 2026-11-13 Market data 2 days old USD 1.17 Healthcare - BiotechnologyAWAIT ENTRY
ACTIONABLEMethodology gates passed
56

Position levels

Currenttoday
USD 1.17
Buy <=wait / entry
USD 0.87
Trim >=take some off
USD 1.40
Thesis breakWithdrawal of the AUCATZYL sales outlook because of sustained adoption weakness,...
-

Scenario-weighted conviction

ProbabilityScoreContribution
Bull case23%100 / 10023.0
Base case49%62 / 10030.4
Bear case28%10 / 1002.8
Weighted conviction56 / 100 - OPPORTUNISTIC BUY

Top risks

  • Raised full-year 2026 AUCATZYL sales guidance to $140 - $150 million from prior $120 - $135 million
  • Q2 2026 AUCATZYL net product revenue of approximately $45 million with 70% QoQ and >100% YoY growth
  • YTD gross margin improvement to approximately 35%
Read full report →

Research is for informational purposes only. Not financial advice. All analysis reflects the date of publication.

\n